Literature DB >> 20388211

Reporting bias in medical research - a narrative review.

Natalie McGauran1, Beate Wieseler, Julia Kreis, Yvonne-Beatrice Schüler, Heike Kölsch, Thomas Kaiser.   

Abstract

Reporting bias represents a major problem in the assessment of health care interventions. Several prominent cases have been described in the literature, for example, in the reporting of trials of antidepressants, Class I anti-arrhythmic drugs, and selective COX-2 inhibitors. The aim of this narrative review is to gain an overview of reporting bias in the medical literature, focussing on publication bias and selective outcome reporting. We explore whether these types of bias have been shown in areas beyond the well-known cases noted above, in order to gain an impression of how widespread the problem is. For this purpose, we screened relevant articles on reporting bias that had previously been obtained by the German Institute for Quality and Efficiency in Health Care in the context of its health technology assessment reports and other research work, together with the reference lists of these articles.We identified reporting bias in 40 indications comprising around 50 different pharmacological, surgical (e.g. vacuum-assisted closure therapy), diagnostic (e.g. ultrasound), and preventive (e.g. cancer vaccines) interventions. Regarding pharmacological interventions, cases of reporting bias were, for example, identified in the treatment of the following conditions: depression, bipolar disorder, schizophrenia, anxiety disorder, attention-deficit hyperactivity disorder, Alzheimer's disease, pain, migraine, cardiovascular disease, gastric ulcers, irritable bowel syndrome, urinary incontinence, atopic dermatitis, diabetes mellitus type 2, hypercholesterolaemia, thyroid disorders, menopausal symptoms, various types of cancer (e.g. ovarian cancer and melanoma), various types of infections (e.g. HIV, influenza and Hepatitis B), and acute trauma. Many cases involved the withholding of study data by manufacturers and regulatory agencies or the active attempt by manufacturers to suppress publication. The ascertained effects of reporting bias included the overestimation of efficacy and the underestimation of safety risks of interventions.In conclusion, reporting bias is a widespread phenomenon in the medical literature. Mandatory prospective registration of trials and public access to study data via results databases need to be introduced on a worldwide scale. This will allow for an independent review of research data, help fulfil ethical obligations towards patients, and ensure a basis for fully-informed decision making in the health care system.

Entities:  

Mesh:

Year:  2010        PMID: 20388211      PMCID: PMC2867979          DOI: 10.1186/1745-6215-11-37

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


  198 in total

1.  Academia and industry: lessons from the unfortunate events in Toronto.

Authors:  D G Nathan; D J Weatherall
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

2.  Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors.

Authors:  Catherine D De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Harold C Sox; Martin B Van Der Weyden
Journal:  N Engl J Med       Date:  2005-05-23       Impact factor: 91.245

3.  Relationship between drug company funding and outcomes of clinical psychiatric research.

Authors:  Robert E Kelly; Lisa J Cohen; Randye J Semple; Philip Bialer; Adam Lau; Alison Bodenheimer; Elana Neustadter; Arkady Barenboim; Igor I Galynker
Journal:  Psychol Med       Date:  2006-08-08       Impact factor: 7.723

4.  Publication bias and the efficacy of antidepressants.

Authors:  Sanjay J Mathew; Dennis S Charney
Journal:  Am J Psychiatry       Date:  2009-02       Impact factor: 18.112

5.  Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee.

Authors:  Erik von Elm; Alexandra Röllin; Anette Blümle; Karin Huwiler; Mark Witschi; Matthias Egger
Journal:  Swiss Med Wkly       Date:  2008-04-05       Impact factor: 2.193

6.  Merck to pay $58m in settlement over rofecoxib advertising.

Authors:  Fred Charatan
Journal:  BMJ       Date:  2008-05-31

7.  Bias in reporting clinical trials.

Authors:  A H Bardy
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

8.  Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals.

Authors:  Kirby P Lee; Elizabeth A Boyd; Jayna M Holroyd-Leduc; Peter Bacchetti; Lisa A Bero
Journal:  Med J Aust       Date:  2006-06-19       Impact factor: 7.738

9.  Reference bias in reports of drug trials.

Authors:  P C Gøtzsche
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-12

10.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

Authors:  R McKenzie; M W Fried; R Sallie; H Conjeevaram; A M Di Bisceglie; Y Park; B Savarese; D Kleiner; M Tsokos; C Luciano
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

View more
  108 in total

1.  Separating the wheat from the chaff: essential information in therapeutics.

Authors:  Roser Llop; Montse Bosch; Albert Figueras; Joan-Ramon Laporte
Journal:  Eur J Clin Pharmacol       Date:  2011-10-21       Impact factor: 2.953

Review 2.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

3.  Publishing "Invisible" and "Abandoned" clinical trials: a commitment for CTS.

Authors:  Arthur M Feldman
Journal:  Clin Transl Sci       Date:  2013-08       Impact factor: 4.689

4.  Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis.

Authors:  Lu Han; Wei Chen; Qicheng Zhao
Journal:  Tumour Biol       Date:  2013-11-12

5.  The health of European medical research. Attempts are under way to update EU regulations, with the aim of harmonizing clinical research across the continent.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2011-02       Impact factor: 8.807

6.  Challenges of translating basic research into therapeutics: resveratrol as an example.

Authors:  James M Smoliga; Ole Vang; Joseph A Baur
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-07-11       Impact factor: 6.053

7.  Critical Evaluation of Pharmacy Automation and Robotic Systems: A Call to Action.

Authors:  Anthony M Boyd; Bruce W Chaffee
Journal:  Hosp Pharm       Date:  2018-07-09

8.  An increasing problem in publication ethics: Publication bias and editors' role in avoiding it.

Authors:  Perihan Elif Ekmekci
Journal:  Med Health Care Philos       Date:  2017-06

9.  Too few trials or too few reported trials?

Authors:  Andrés Viteri-García; Nicholas J DeVito; Ben Goldacre
Journal:  Evid Based Dent       Date:  2018-10

Review 10.  Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Authors:  Dirk Eyding; Monika Lelgemann; Ulrich Grouven; Martin Härter; Mandy Kromp; Thomas Kaiser; Michaela F Kerekes; Martin Gerken; Beate Wieseler
Journal:  BMJ       Date:  2010-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.